Saeki, Sumito http://orcid.org/0009-0001-8225-923X
Iwatani, Tsuguo http://orcid.org/0000-0001-7162-1515
Kitano, Atsuko http://orcid.org/0000-0001-8881-3329
Sakurai, Naomi
Tanabe, Yuko
Yamauchi, Chikako http://orcid.org/0000-0003-1799-8535
Igarashi, Ataru http://orcid.org/0000-0001-6307-6916
Kajimoto, Yusuke http://orcid.org/0000-0003-3681-5757
Kuba, Sayaka http://orcid.org/0000-0002-0225-099X
Hara, Fumikata http://orcid.org/0000-0001-8025-3494
Sagara, Yasuaki http://orcid.org/0000-0001-5705-1739
Ohno, Shinji http://orcid.org/0000-0003-2093-3353
,
Funding for this research was provided by:
Japanese Breast Cancer Society (25)
Article History
Received: 20 April 2023
Accepted: 5 June 2023
First Online: 13 June 2023
Change Date: 3 July 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12282-023-01479-w
Declarations
:
: AI reports consultancy fees, grants, and other payments from multiple companies, including Pfizer Japan Inc., Terumo Corporation, Becton Dickinson and Company, Milliman Inc., Taiho Pharmaceutical Co. Ltd., Abbvie GK, Ayumi Pharmaceutical Inc., Chugai Pharmaceuticals Inc., Eisai Inc., GSK, Nippon Boehringer Ingelheim Inc., Novartis Pharma K.K., Novo Nordisk Japan Inc., Ono Pharmaceutical Inc., Sumitomo Dainippon Pharma Inc., Takeda Pharmaceutical Inc., Otsuka Pharmaceutical Co., Ltd., Sanofi Japan Inc., Gilead Sciences K.K., Boston Scientific Japan Inc., Intuitive Surgical GK, Astellas Pharma Inc., CSL Behring Japan Inc., Fuji Film Inc., and Medilead Inc. YK is an employee of MSD K.K. FH has received payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Kyowa Kirin, Pfizer, Eli Lilly, Chugai, and Eisai. The other authors declare that they have no conflict of interest.
: Participants provided informed consent on the application before the survey. The protocol was approved by the Institutional Ethics Committee of the Cancer Institute Hospital of the Japan Cancer Institute, the lead investigator of the group study (No. 2020–1151), and the collaborating institutions followed suit.